Sagimet Biosciences Inc. Series A (SGMT)
NASDAQ: SGMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SGMT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $648.02M
- EPS (TTM)
- -$1.18
- Dividend yield
- None
- 52-week range
- 4.50 – 11.45
- Day range
- 8.83 – 9.40
- Volume / Avg
- 1.50M / 1.23M
- Beta
- —
- Shares outstanding
- 71.37M
52-week range
SGMT stock today
Shares of Sagimet Biosciences Series A (SGMT) finished lower on Nov 20 at $9.08, a drop of 5.61% or $0.54 per share, versus the S&P 500's 3.70% decline. Shares are 20.7% below their 52-week high of $11.45, set on Sep 10, 2026 and 101.8% above the 52-week low of $4.50, in the middle of the past year's range. SGMT is up 53.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.1%.
Sagimet Biosciences Series A has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sagimet Biosciences Series A
Company profileSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. David A. Happel
- Headquarters
- San Mateo, CA
- Employees
- 16
- IPO year
- 2023
- Website
- sagimet.com
Financial highlights
Full financialsSagimet Biosciences Series A reported a net loss of $51.0 million, compared with a loss of $45.6 million a year earlier. Diluted earnings per share came in at -$1.58.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | $2.00M | — |
| Growth | — | — | — | — |
| Net income | $-51.04M | $-45.57M | $-27.88M | $-30.50M |
| EPS (diluted) | $-1.58 | $-1.45 | $-2.66 | $-165.20 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$27.27+200.33%
- Strong buy 2
- Buy 9
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.31 vs $-0.25
- Surprise
- -24.00%
SGMT news
All SGMT news- Sagimet Biosciences Inc. Reports Third Quarter 2026 Financial Results and Pro Forma Cash of Approximately $356 millionNasdaqSGMT, WSO.B
- Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Sagimet Biosciences Inc. Announces Clinical Updates for Denifanstat and TVB-3567Nasdaq
- Tuesday's ETF Movers: XBI, CRAKNasdaqMYGN, SGMT, MPC, PSX
- Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceGlobeNewswire
- Notable Monday Option Activity: ONT, NET, SGMTNasdaqONT, NET, SGMT
Sagimet Biosciences Series A peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs SGMT |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs SGMT |
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs SGMT |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs SGMT |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs SGMT |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs SGMT |
| LXRXLexicon Pharmaceuticals Inc. | 1.53 | -8.38% | $681.21M | vs SGMT |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs SGMT |
Indexes, lists and sector
Sagimet Biosciences Series A stock FAQ
What is Sagimet Biosciences Series A's stock price today?
SGMT last traded at $9.08 as of Nov 20, 4:00 PM EST, down 5.61% on the day. Prices are delayed at least 15 minutes.
Who is Sagimet Biosciences Series A's CEO?
Mr. David A. Happel is the chief executive officer of Sagimet Biosciences Inc. Series A, which has about 16 employees.
What is the SGMT 52-week high?
The 52-week high for SGMT is $11.45 and the 52-week low is $4.50. The stock is currently 20.7% below its high.